http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10045981-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5736af47d69e0faa36097a4f2c3656bd |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-498 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D241-42 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-498 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D241-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-10 |
| filingDate | 2016-11-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-08-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fba79de16dce3f30c39286bc10a74912 |
| publicationDate | 2018-08-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-10045981-B2 |
| titleOfInvention | Selective kinase inhibitors |
| abstract | The present disclosure relates to methods of modulating (for example, inhibiting) activity of JAK3, comprising contacting the JAK3 with a compound of Formula I or pharmaceutically acceptable salt thereof, wherein constituent members are provided hereinwith. The present disclosure further provides novel compounds and compositions as well as their methods of preparation and use. The disclosed JAK3 inhibitors may be used in the treatment of JAK3-associated diseases including, for example, inflammatory and autoimmune disorders. |
| priorityDate | 2015-11-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 293.